Kelly Lab USC

The official account of Dr. Kevin Kelly’s Hematology Research Lab @uscnorris | Translational Research | Clinical Trials |

[Kelly Lab USC @KellyLabUSC]

@HomaDadras @EHA_Hematology Well done Homa! Congratulations on your excellent poster and your EHA award!

[Homa Dadras, MD @HomaDadras]

It was a great experience attending #EHA2025 and even more meaningful to be awarded the travel grant.
Proud to be part of this incredible community and to learn from the forefront of hematology research.
@EHA_Hematology

[Cancer Cell @Cancer_Cell]

The discrete charm of oncolytic viruses: Toward the finish line https://t.co/QY4WVSllsX

[Homa Dadras, MD @HomaDadras]

Excited for the #AACRIO25 !

[Kelly Lab USC @KellyLabUSC]

Young researchers at Kelly Lab!
@uscnorris

[Kelly Lab USC @KellyLabUSC]

Working with a view in Kelly Lab!
Happy Friday everyone!

[PHASE ONE Foundation @PhaseOneLA]

Learn more about Dr. Kelly's PHASE ONE-funded trial ⤵️

https://t.co/GXRQTeMMLg

[PHASE ONE Foundation @PhaseOneLA]

THANK YOU, Dr. Kelly, and your team, for your dedication to finding new and better treatments for patients with multiple myeloma. 🫶

[PHASE ONE Foundation @PhaseOneLA]

"PHASE ONE has enabled us to translate our bench research into the clinic and opened the door to immune checkpoint therapy for myeloma patients –– transforming early-phase research and making clinical trials available to the patients that need them most."

~Dr. Kelly

[PHASE ONE Foundation @PhaseOneLA]

Today's #FacesofPHASEONE is highlighting Dr. Kevin Kelly at @USC.

Dr. Kelly received a Medical Grant from PHASE ONE in 2022 for his novel combination therapy for patients with multiple myeloma.

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: CD4+ CAR-T cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR-T cell therapy, possibly through non-classical monocytes: https://t.co/06GbLjqGoG.

[Kelly Lab USC @KellyLabUSC]

@DAVAOnc
#DAVAWhistlerHeme
@uscnorris

[Kelly Lab USC @KellyLabUSC]

Having fun at #DavaWhistler! Learning a lot and sneaking in some fun in the snow!

[Kelly Lab USC @KellyLabUSC]

Excited to announce that David Drum presented our ongoing trial at @KeystoneSymp 2024!

He showcased “Using #IMC to analyze changes in #MultipleMyeloma TME following pembrolizumab and oncolytic virus therapy in a Phase 1b/2 trial.”
@uscnorris

[USC Norris Comprehensive Cancer Center @uscnorris]

Published in Nature Cancer, Dr. @RoussosTorres & her team, with researchers at @JohnsHopkins, discovered that pre-treatment with entinostat, w/ the use of dual-immune checkpoint inhibitors is a safe & promising strategy for metastatic #breastcancer.

https://t.co/tefLc7c0nZ

[Kelly Lab USC @KellyLabUSC]

Starting the new year with positive energy! Excited for our ongoing projects and new opportunities ahead in 2024!
#KellyLabUSC @uscnorris
#hematology

[Kelly Lab USC @KellyLabUSC]

We are thrilled to announce that our recent research work got featured on the cover page of @CCR_AACR

The cover shows a section of a BM biopsy from a patient with #MultipleMyeloma treated with Pela/BZ/Dex. #IMC shows histone H3 in blue, CD138 in red, cleaved caspase 3 in green.

[Homa Dadras, MD @HomaDadras]

Wow! So excited to have our work featured on the cover of Clinical Research Cancer!
@CCR_AACR
#IMC
#MultipleMyeloma

[Clinical Cancer Research @CCR_AACR]

The December 15 issue is online.
https://t.co/ynSVIkltMS

[Homa Dadras, MD @HomaDadras]

Exploring the BM TiME in #MultipleMyeloma patients through IMC and observing the cellular dynamics in response to Pela/BZ/Dex.

Check out our cool #IMC images!
#ImageMassCytometry #pelareorep